Update on adverse drug events associated with parenteral iron.
about
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agentsRole of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patientsSafety of intravenous iron formulations: facts and folklorePrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironIron deficiency in gastrointestinal oncologyThe treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice GuidelAnemia and iron deficiency in gastrointestinal and liver conditionsConsiderations and challenges in defining optimal iron utilization in hemodialysisIntravenous iron therapy: how far have we come?Safety of intravenous iron in hemodialysis patients.Ferumoxytol for the treatment of iron deficiency.Data mining of the public version of the FDA Adverse Event Reporting SystemCommonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency AnemiaTreatment of iron deficiency anemia associated with gastrointestinal tract diseases.A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.[Preoperative anemia in orthopedic surgery: clinical impact, diagnostics and treatment].The pharmacokinetics and pharmacodynamics of iron preparations.Alternative procedures for reducing allogeneic blood transfusion in elective orthopedic surgery.Diagnosis and management of iron deficiency anemia in patients with IBD.Indications and organisational methods for autologous blood transfusion procedures in Italy: results of a national surveyHypersensitivity reactions to intravenous iron: guidance for risk minimization and management.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapyA randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.Physical and chemical stability of iron sucrose in parenteral nutrition.Intravenous iron supplementation may be superior to observation in acute isovolemic anemia after gastrectomy for cancerOh the irony: Iron as a cancer cause or cure?Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol.Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic ReviewOn the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat modelIs there any role of intravenous iron for the treatment of anemia in cancer?Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia.The role of intravenous iron in the treatment of anemia in cancer patients
P2860
Q24186166-83B4B923-6ABE-4691-9CFE-5277D30263CEQ24203798-9BB3513F-7424-4AF3-9733-76B61821A09AQ26853397-52A0011B-A97E-47F1-9840-06BBE384FF09Q27004170-8404137C-0A62-4AEC-99A1-B65D676B8B9EQ27023196-EF76EC32-D579-4231-980E-EE8838281B52Q27024854-2476CE7F-FDC6-4265-9C1D-C55BA5C2B808Q28069820-4D242F05-0ECE-411E-91DE-8A47F2D8977CQ28088564-B322E045-7F9C-417D-8860-0E58CD8AB388Q28276678-2023B635-CCBF-48B4-A5F3-B206B3921982Q30234981-A54CB067-7A0A-4841-B5D1-F4C32DFB641BQ30454001-19EC41B8-2742-48C0-93D6-FDE6BD0DF288Q30651235-A6D8BD54-3385-49DA-9E58-ACB8719F3D1DQ30790443-94D08B47-A9B3-46A6-82F6-6A8BF7837EE9Q31045009-D1B70921-F55C-4EC2-B3BE-900EB9A613C7Q33607976-B9010AF3-18D6-458F-B9CD-AACD8970410AQ33903592-BE62D028-6881-4F10-920A-59EA2C4CD5D2Q34010689-9BA27FE8-48EA-4201-BD54-F748D3F812FEQ34020541-A9F044AA-20C4-4459-B374-17A5C0730E8DQ34039226-C1DCF06D-6C6F-4E2D-90A8-687BDD274B48Q34079843-32BFC593-8C77-44EB-8E98-65E9F3D49392Q34141999-EF88CC9F-DFE1-4D66-9FD8-8CE91861DFC3Q34416339-06D0EFA5-511E-49A4-BEA3-A20A10DDE366Q34463623-5E97C217-5BC6-4041-A0AD-C78FD57143E4Q34635638-F545D646-9766-4F80-A006-5594A3753312Q34654443-3BA30E2A-ADD5-4FB9-A61A-2CCFA818EB4EQ34710712-B99E90A6-BCD4-482A-A365-3C73A019D7A1Q34821739-0FA86742-55B4-4842-A769-9A5DF6D7D4AFQ34885195-8B8E1B86-57AF-450B-B229-99D97F28C4C2Q35015688-7EF3FE1D-29C2-4753-8732-F8A5201EC9EEQ35109243-81189AEA-A1FD-4039-BFB6-E852DFE412A8Q35343242-2D7A40AB-DD24-4F01-8A0E-67317DAEBF39Q35574227-60A20C88-AF0C-4D46-ABF1-5C29D6BA50A0Q35659768-298FE538-139E-48BA-9E79-231FE1028FCAQ35674624-17A3C2A7-108A-442E-A4A7-30521EAE9F02Q35898038-871A72E3-7474-47BD-81D4-8E31EC3EF7B0Q35931905-330A88E4-66B1-42C5-B7F1-A66087930623Q36108113-75F9E983-FCB2-4CF7-A6DC-74DA319635D1Q36263980-DB493696-268C-4C9F-A7CC-1DBF663B5057Q36283062-E5038E6A-95FA-4293-9323-E27747578E5DQ36612686-57F6E0E2-E9A1-4B9C-A330-106C409B5728
P2860
Update on adverse drug events associated with parenteral iron.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Update on adverse drug events associated with parenteral iron.
@en
Update on adverse drug events associated with parenteral iron.
@nl
type
label
Update on adverse drug events associated with parenteral iron.
@en
Update on adverse drug events associated with parenteral iron.
@nl
prefLabel
Update on adverse drug events associated with parenteral iron.
@en
Update on adverse drug events associated with parenteral iron.
@nl
P2093
P2860
P356
P1476
Update on adverse drug events associated with parenteral iron.
@en
P2093
Glenn M Chertow
Jarl Ahlmén
Odd Vaage-Nilsen
Phillip D Mason
P2860
P304
P356
10.1093/NDT/GFI253
P407
P577
2005-11-11T00:00:00Z